Hyundai Chinese Medicine Group (01643) is expected to achieve a net loss of about 25.9 million yuan in the medium term, a year-on-year profit to loss

According to Zhitong Finance App, Modern Chinese Medicine Group (01643) issued an announcement. Based on a preliminary assessment of the Group's unaudited comprehensive management accounts for the six months ended June 30, 2026 (this period) and data currently available to the board of directors, the Group is expected to achieve a net loss of approximately RMB 25.9 million during the period and a net profit of approximately RMB 2.5 million for the year ended June 30, 2025.

According to the director's knowledge, the shift from net profit to net loss was mainly due to 1) an increase in promotion and marketing expenses in cooperation with the expansion of business in East China; and 2) an increase in R&D costs to improve product quality and enhance clinical value research.